Catalyst Awardee

Project Description

Research and Development of Chamaejasmenin B for the Treatment of Ischemic Stroke

Jiekun Xu, PhD | Beijing University of Chinese Medicine;Weiku Zhang, PhD; Jun He, PhD 
Competition Sponsor:
 Chinese Academy of Medical Sciences
Awardee Year: 2023

Ischemic stroke seriously endangers the people health, however, there is still a significant lack of effective therapeutic drugs in clinical practice. Our team has discovered in recent years that Chamaejasmenin B isolated from the traditional Chinese medicine Stellera chamaejasme L. has significant treatment effect of ischemic stroke.There is a good neuroprotective effect on transient middle cerebral artery occlusion (tMCAO) injury in rats in vivo, which can improve histology after ischemia and promote neurobehavioral recovery. At the same time, it can regulate the balance of oxidative antioxidant system in brain tissue of rats with cerebral ischemia-reperfusion, and reduce the level of inflammatory factors. In addition, the results of toxicity studies in animals showed that Chamaejasmenin B has no obvious toxic or side effects. If Chamaejasmenin B is successfully developed, it will provide an innovative drug with high safety, definite treatment of ischemic stroke.

Sign up for updates